Company intelligence / Profile preview

TwinStrand Biosciences

Seattle, Washington, United Statestwinstrandbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

TwinStrand's Duplex Sequencing technology reduces sequencing error rates from 1-in-100 to 1-in-10 million, allowing detection of ultra-low frequency mutations with 10,000x greater sensitivity than conventional tools. The technology is being applied to cancer detection, residual disease monitoring, and genetic toxicology applications.

Therapeutic areas: OncologyRare Diseases
Modalities: DNA sequencing technology
Industry: Molecular Diagnostics

Partnerships

Exact Sciences

Beyond the preview

Go deeper on TwinStrand Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TwinStrand Biosciences.

Explore the full profile